Luminex Corporation, a leader in multiplexed solutions, released its FLEXMAP 3DTM system, a high-throughput multiplexing instrument that allows scientists to simultaneously perform up to 500 tests on a single sample.
Created with input from scientists worldwide, FLEXMAP 3D was designed to meet the needs of medium and high-volume laboratories, such as academic, reference and pharmaceutical research laboratories. The FLEXMAP 3D multiplexing system’s ability to conduct many tests at once can significantly enhance the efficiencies of life sciences research and drug discovery.
This system was created for scientists who were seeking a faster throughput instrument with higher multiplexing capability. Based on Luminex’s flexible xMAP Technology, FLEXMAP 3D fills an essential segment between the low multiplex marketplace and the high multiplex microarray market. The robust system provides scientists at medium and high volume laboratories significantly enhanced throughput, higher multiplexing, with up to 500 analytes per well, improved analytical performance, 96 or 384 well plate format, enhanced dual pipetting, automation and LIS compatibility, streamlined calibration and performance verification routines and easy maintenance with a simple workflow.
FLEXMAP 3D can perform multiplexed genomic, transcriptomic, and proteomic biomarker analysis on a single platform. FLEXMAP 3D is ideal for applications such as SNP genotyping and gene expression analysis, which are vital in areas such as high throughput pharmaceutical research. By enabling research to proceed more efficiently, the system allows faster screening of novel targets and an overall improvement in laboratory management.
Luminex has shipped a number of the FLEXMAP 3D systems to customers since the first commercial shipment in November 2008. These include pharmaceutical and research laboratories that have adopted the system because of its increased throughput and multiplexing capabilities.
Filed Under: Drug Discovery
